Free Trial

Arcus Biosciences (RCUS) Stock Price, News & Analysis

Arcus Biosciences logo
$9.42 -0.16 (-1.68%)
Closing price 03/10/2025 03:59 PM Eastern
Extended Trading
$9.81 +0.40 (+4.19%)
As of 07:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Arcus Biosciences Stock (NYSE:RCUS)

Key Stats

Today's Range
$9.01
$9.62
50-Day Range
$9.42
$15.19
52-Week Range
$9.01
$19.35
Volume
1.58 million shs
Average Volume
716,695 shs
Market Capitalization
$990.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.25
Consensus Rating
Buy

Company Overview

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Remove Ads

Arcus Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

RCUS MarketRank™: 

Arcus Biosciences scored higher than 46% of companies evaluated by MarketBeat, and ranked 546th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arcus Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Arcus Biosciences has only been the subject of 3 research reports in the past 90 days.

  • Read more about Arcus Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Arcus Biosciences are expected to decrease in the coming year, from ($3.15) to ($4.73) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arcus Biosciences is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arcus Biosciences is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arcus Biosciences has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Arcus Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    11.13% of the float of Arcus Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcus Biosciences has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in Arcus Biosciences has recently increased by 1.41%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Arcus Biosciences does not currently pay a dividend.

  • Dividend Growth

    Arcus Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.13% of the float of Arcus Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcus Biosciences has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in Arcus Biosciences has recently increased by 1.41%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Arcus Biosciences has a news sentiment score of -0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Arcus Biosciences this week, compared to 5 articles on an average week.
  • Search Interest

    2 people have searched for RCUS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Arcus Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arcus Biosciences insiders have bought 647.10% more of their company's stock than they have sold. Specifically, they have bought $402,764.00 in company stock and sold $53,910.00 in company stock.

  • Percentage Held by Insiders

    12.30% of the stock of Arcus Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    92.89% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arcus Biosciences' insider trading history.
Receive RCUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RCUS Stock News Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Morgan Stanley Remains a Buy on Arcus Biosciences (RCUS)
Leerink Partnrs Expects Lower Earnings for Arcus Biosciences
HC Wainwright Analysts Raise Earnings Estimates for RCUS
Q1 EPS Forecast for Arcus Biosciences Boosted by Analyst
See More Headlines

RCUS Stock Analysis - Frequently Asked Questions

Arcus Biosciences' stock was trading at $14.89 on January 1st, 2025. Since then, RCUS shares have decreased by 36.7% and is now trading at $9.4190.
View the best growth stocks for 2025 here
.

Arcus Biosciences, Inc. (NYSE:RCUS) released its quarterly earnings data on Tuesday, February, 25th. The company reported ($1.03) earnings per share for the quarter, beating the consensus estimate of ($1.17) by $0.14. The firm earned $36 million during the quarter, compared to the consensus estimate of $29.38 million. Arcus Biosciences had a negative trailing twelve-month return on equity of 45.59% and a negative net margin of 102.66%.

Arcus Biosciences (RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

Arcus Biosciences' top institutional investors include Gilead Sciences Inc. (32.85%), Vanguard Group Inc. (5.89%), Woodline Partners LP (3.85%) and Point72 Asset Management L.P. (2.18%). Insiders that own company stock include Gilead Sciences, Inc, Terry J Rosen, Juan C Jaen, Jennifer Jarrett, Robert C Goeltz II, Carolyn C Tang, Yasunori Kaneko and Alexander Azoy.
View institutional ownership trends
.

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcus Biosciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
2/25/2025
Today
3/11/2025
Next Earnings (Estimated)
5/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:RCUS
Fax
N/A
Employees
500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.25
High Stock Price Target
$44.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+221.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-307,000,000.00
Net Margins
-102.66%
Pretax Margin
-102.28%

Debt

Sales & Book Value

Annual Sales
$258 million
Price / Cash Flow
N/A
Book Value
$6.17 per share
Price / Book
1.53

Miscellaneous

Free Float
80,256,000
Market Cap
$990.29 million
Optionable
Optionable
Beta
1.36
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NYSE:RCUS) was last updated on 3/11/2025 by MarketBeat.com Staff
From Our Partners